SCHEMBL20265623

SCHEMBL20265623

CCOC(=O)c1cnn(-c2cccc3ncccc23)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MALT1 Q9UDY8 2/20 0.51
MAOB P27338 1/20 0.47
MAPT P10636 4/20 0.47
HTT P42858 1/20 0.47
SLC9A1 P19634 1/20 0.46
ELANE P08246 5/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
RECQL P46063 1/20 0.45
MAPK10 P53779 1/20 0.45
LMNA P02545 3/20 0.45
RAB9A P51151 2/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
PTK2B Q14289 1/20 0.45
METAP1 P53582 1/20 0.43
POLB P06746 1/20 0.41
ALOX15 P16050 1/20 0.40
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6318424 0.83 ALDH1A1 (0.42) MAOBMAPTELANESMN1; SMN2RECQL
SCHEMBL1195182 0.78 MAPK11 (0.48) MAPTSMN1; SMN2RAB9APOLBALOX15
SCHEMBL12571590 0.78 MAOB (0.46) MAOBRAB9AALOX15TSHR
SCHEMBL6314486 0.77 SLC9A1 (0.65) MALT1MAPTSLC9A1ELANERAB9A
SCHEMBL18617388 0.76 TRPV1 (0.49) MAPTELANESMN1; SMN2LMNARAB9A
SCHEMBL14692553 0.76 PDE4B (0.44) MAPTHTTSMN1; SMN2LMNARAB9A
SCHEMBL30535434 0.76 EGLN1 (0.64) MAOBMAPTHTTSMN1; SMN2LMNA
SCHEMBL2159904 0.76 EGLN1 (0.64) MAOBMAPTHTTSMN1; SMN2LMNA
SCHEMBL2439454 0.76 PDE4B (0.52) MAPTLMNARAB9APOLB
SCHEMBL20265483 0.76 SLC9A1 (0.54) MALT1MAPTSLC9A1ELANERAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3558969-B1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2024-09-18 EP disclosed
US-12077521-B2 Pyrazole derivatives as MALT1 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2024-09-03 US disclosed
US-20220315557-A1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS JANSSEN BIOTECH, INC. 2022-10-06 US disclosed
US-10954214-B2 Pyrazole derivatives as MALT1 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2021-03-23 US disclosed
US-10954214-B2 Pyrazole derivatives as MALT1 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2021-03-23 US disclosed
EP-3558969-A1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS Janssen Pharmaceutica NV (BE) 2019-10-30 EP disclosed
WO-2018119036-A1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS JANSSEN BIOTECH, INC. (US) 2018-06-28 WO disclosed
WO-2018119036-A1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS JANSSEN BIOTECH, INC. (US) 2018-06-28 WO disclosed
US-20180170909-A1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS JANSSEN-CILAG (FR) 2018-06-21 US disclosed
US-20180170909-A1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS JANSSEN-CILAG (FR) 2018-06-21 US disclosed
US-20180170909-A1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS JANSSEN-CILAG (FR) 2018-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220315557-A1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS MALT1, PPP3R1, SQSTM1 MALT1 1/4885MAOB 3636/4885MAPT 2314/4885
US-10954214-B2 Pyrazole derivatives as MALT1 inhibitors MALT1, PPP3R1, SQSTM1 MALT1 1/4885MAOB 3636/4885MAPT 2314/4885
US-12077521-B2 Pyrazole derivatives as MALT1 inhibitors MALT1, PPP3R1, SQSTM1 MALT1 1/4885MAOB 3636/4885MAPT 2314/4885
US-20180170909-A1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS MALT1, PPP3R1, SQSTM1 MALT1 1/4885MAOB 3636/4885MAPT 2314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.